Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is a novel beta coronavirus. SARS-CoV-2 uses spike glycoprotein to interact with host angiotensin-converting enzyme 2 (ACE2) and ensure cell recognition. High infectivity of SARS-CoV-2 rai...
Main Authors: | Masaud Shah, Bilal Ahmad, Sangdun Choi, Hyun Goo Woo |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-01-01
|
Series: | Computational and Structural Biotechnology Journal |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2001037020304694 |
Similar Items
-
Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2
by: Margherita Passariello, et al.
Published: (2021-05-01) -
SAS: A Platform of Spike Antigenicity for SARS-CoV-2
by: Lu Zhang, et al.
Published: (2021-09-01) -
Characterization of Critical Determinants of ACE2–SARS CoV-2 RBD Interaction
by: Emily E. F. Brown, et al.
Published: (2021-02-01) -
Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2
by: Ma’mon M. Hatmal, et al.
Published: (2020-12-01) -
Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity
by: Thomas Phelan, et al.
Published: (2021-07-01)